With funding and business development support from the Blavatnik Biomedical Accelerator, a research team’s lab discovery propelled to startup success.

Kinvard Bio is creating a new class of antibiotics to treat drug-resistant infections and diseases.

Scientists zoom in on microbial messages at the molecular level to understand how the microbiome shapes health.

GC Therapeutics (GCTx), a Harvard startup, announced its launch to scale and its technology TFome™, the world’s first “plug and play” induced pluripotent stem cell (iPSC) programming platform for cell therapies in multiple therapeutic areas.